The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 379-385

  Sakashita, Fumio ^a   Osada, Shinji ^a   Takemura, Masao ^a   Imai, Hisashi ^a   Tomita, Hiroyuki ^a   Nonaka, Kenichi ^a   Takahashi, Takao ^a   Seishima, Mitsuru ^a  

^a Graduate School of Medicine   (Japan)

Author keywords

Apoptosis; Caspase 3; Cyclin B1; p53 Expression; Paclitaxel

Indexed keywords

CASPASE 3; CYCLIN B1; PACLITAXEL; PIFITHRIN ALPHA; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME DEGRADATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CLONING, MOLECULAR; CYCLIN B; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45749114171     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0614-5     Document Type: Article

References (41)

1. Cutsem EV (2004) The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 9:9-15
2. Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41
3. Glimelius B, Ekström K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
4. Chang YF, Li LL, Wu CW et al (1996) Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77:14-18
5. Hironaka S, Zenda S, Boku N et al (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14-18
6. Yamada Y, Shirao K, Ohtsu A et al (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133-1137
7. Ohtsu A, Boku N, Tamura F et al (1998) An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416-419
8. Amos LA, Löwe J (1999) How taxol stabilises microtubule structure. Chem Biol 6:65-69
9. Crown J, O'Leary M (2000) The taxanes: an update. Lancet 355:1176-1178
10. Yoo YD, Park JK, Choi JY et al (1998) CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells. Clin Cancer Res 4:3063-3068
11. Mullan PB, Quinn JE, Gilmore PM et al (2001) BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20:6123-6131
12. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495
13. Kastan MB, Onyekwere O, Sidransky D et al (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
14. Petak I, Tillman DM, Houghton JA (2000) P53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 6:4432-4441
15. Matsuhashi N, Saio M, Matsuo A et al (2004) Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 24:807-813
16. Lavarino C, Pilotti S, Oggionni M et al (2000) P53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18:3936-3945
17. Debernardis D, Siré EG, Feudis PD et al (1997) P53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57:870-874
18. Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79
19. Osada S, Imai H, Tomita H et al (2006) Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J Gastroenterol Hepatol 21:988-993
20. Osada S, Saji S, Osada K (2001) Critical role of extracellular signal-regulated kinase phosphorylation on menadione (vitamin K3) induced growth inhibition. Cancer 91:1156-1165
21. Komarov PG, Komarova EA, Kondratov RV et al (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285:1733-1737
22. Rocha S, Campbell KJ, Roche KC, Perkins ND (2003) The p53-inhibitor pifithrin-α inhibits firefly luciferase activity in vivo and in vitro. BMC Mol Biol 4:9
23. Pirollo KF, Bouker KB, Chang EH (2000) Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11:419-432
24. Bates S, Vousden KH (1999) Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28-37
25. Stürzbecher HW, Chumakov P, Welch WJ, Jenkins JR (1987) Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV 40-transformed monkey cells. Oncogene 1:201-211
26. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) P53 mutations in human cancers. Science 253:49-53
27. Kim R, Tanabe K, Inoue H, Toge T (2002) Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol 20:549-555
28. Woods CM, Zhu J, McQueney PA et al (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506-526
29. Torres K, Horwitz SB (1998) Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58:3620-3626
30. Morrison DK, Cutler RE (1997) The complexity of Raf-1 regulation. Curr Opin Cell Biol 9:174-179
31. Blagosklonny MV, Giannakakou P, El-Deiry WS et al (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57:130-135
32. Joshi B, Rastogi S, Morris M et al (2007) Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 sites. Biochem J 401(1):155-166
33. Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27-36
34. Osada S, Kanematsu M, Imai H et al (2005) Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg 201:405-411
35. Castedo M, Perfettini JL, Roumier T et al (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23:2825-2837
36. Cappelletti V, Fioravanti L, Miodini P, Di Fronzo G (2000) Genistein blocks breast cancer cells in the G2/M phase of the cell cycle. J Cell Biochem 79:594-600
37. Kasahara T, Kuwayama C, Hashiba M et al (2003) The gene expression of hepatic proteins responsible for DNA repair and cell proliferation in tamoxifen-induced hepatocarcinogenesis. Cancer Sci 94:582-588
38. Innocente SA, Abrahamson JLA, Cogswell JP, Lee JM (1999) P53 regulates a G2 checkpoint though cyclin B1. Proc Natl Acad Sci USA 96:2147-2152
39. Ianzini F, Bertoldo A, Kosmacek EA et al (2006) Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells. Cancer Cell Int 6:11
40. Okano J, Rustgi AK (2001) Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 276:19555-19564
41. Huisman C, Ferreira CG, Bröker LE et al (2002) Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 8:596-606